Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 24,490	$ 11,345
General and administrative	7,435	2,716
Total operating expenses	31,925	14,061
Loss from operations	(31,925)	(14,061)
Other income
Change in fair value of antidilution rights liability	0	396
Change in fair value of success payment liability	1,677	382
Interest and other income, net	82	20
Total other income, net	1,759	798
Net loss	$ (30,166)	$ (13,263)
Net loss per common share attributable to common stockholders, basic and diluted	$ (0.62)	$ (4.99)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted	48,571,214	2,656,278
Comprehensive Loss:
Net loss	$ (30,166)	$ (13,263)
Other comprehensive loss:
Unrealized loss on marketable securities	(504)	(1)
Comprehensive loss	$ (30,670)	$ (13,264)